# ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

> **NCT07284420** · PHASE2 · RECRUITING · sponsor: **argenx** · enrollment: 70 (estimated)

## Conditions studied

- AChR-Ab Seropositive Generalized Myasthenia Gravis
- Myasthenia Gravis
- MG
- gMG
- Generalized Myasthenia Gravis
- Generalized Myasthenia Gravis (gMG)

## Interventions

- **BIOLOGICAL:** Efgartigimod IV
- **BIOLOGICAL:** Empasiprubart IV

## Key facts

- **NCT ID:** NCT07284420
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-19
- **Primary completion:** 2028-03-07
- **Final completion:** 2028-03-07
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07284420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07284420, "ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07284420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*